Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Recurrence × Data Collection × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Papillomavirus Infections 7 Uterine Cervical Neoplasms 4 Neuroendocrine Tumors 4 Neoplasms 4 Autoimmune Diseases 3 Ovarian Neoplasms 2 Myasthenia Gravis 2 Mesothelioma, Malignant 2 Venous Thrombosis 1 Venous Thromboembolism 1 Thyroid Diseases 1 Thrombosis 1 Retinal Telangiectasis 1 Renal Insufficiency 1 Recurrence 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Mesothelioma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphohistiocytosis, Hemophagocytic 1 Lung Neoplasms 1 Leukemia, Hairy Cell 1 Hemorrhage 1 Hematologic Neoplasms 1 Fanconi Anemia, Complementation Group D1 1 Desmoid Tumors 1 Cysts 1 Colonic Neoplasms 1

Interventions

Cyclophosphamide 57 Dexamethasone 46 Lenalidomide 32 Rituximab 30 Peripheral Blood Stem Cell Transplantation 28 Bortezomib 26 fludarabine phosphate 25 Filgrastim 25 Carboplatin 23 Etoposide 22 Radiotherapy 21 Melphalan 20 Paclitaxel 19 Busulfan 19 Cytarabine 18 Whole-Body Irradiation 17 Gemcitabine 17 Cyclosporine 17 pomalidomide 16 Mycophenolic Acid 16 Bevacizumab 16 pembrolizumab 15 fludarabine 15 Cisplatin 15 Methotrexate 13 Calcium Dobesilate 12 venetoclax 11 Tacrolimus 11 Nivolumab 11 Bendamustine Hydrochloride 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02262273 2017-03-01

OSCA

AstraZeneca

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡